The Anti Fungal Agent Market growth is increasing due to rise in number of patients suffering from hygiene related diseases in developing countries and some of the developed countries. Anti fungal agent is a drug that detects and eliminates fungal pathogens from foreign body with minimal toxic side effects to the body. The global market for anti fungal agents is expected to reach approximately $102 billion by 2015.
High penetration of conventional drugs used in the treatment of fungal diseases is reducing the growth for anti-fungal agent market. Though these restraints are dominating the market, the application of anti fungal drugs market has initiated the growth of anti fungal agent market. The challenges faced by this market are expected to resolve, as companies are concentrating on advancement in technologies that reduces the cost and increases the efficiency of the treatment. The report provides intelligence on patent analysis that provides forecasted market trends for anti fungal agents. The report also provides intelligence about competitive landscape for key companies engaged in this business.
Get the PDF brochure of this market insight@ https://www.alliedmarketresearch.com/request-toc-and-sample/76
Key companies included in company profiles are Asperqillus, Alternaria, Abbott Laboratories, Pfizer, Glaxosmithkline, Bayer Healthcare, Novartis, Sanofi-Aventis, Merck & Co., Kramer Laboratories, Enzon Pharmaceuticals, and Gilead.
KEY MARKET SEGMENTS
BY DRUG TYPES
BY THERAPEUTIC INDICATIONS